Dr. Papadimitrakopoulou on Role of Immunotherapy in Lung Cancer

Vassiliki A. Papadimitrakopoulou, MD
Published: Friday, Feb 03, 2017



Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the subset of patients with lung cancer which would derive the most benefit from immunotherapy.

Patients with lung cancer who have a high expression of PD-L1—in more than 50% of cells—are found to benefit from PD-L1 monotherapy. It is not certain whether this is the best way to indicate eligibility for immunotherapy.

Although, with the recent approval of pembrolizumab (Keytruda), this subset of patients should also be considered for upfront immunotherapy, says Papadimitrakopoulou.
 
SELECTED
LANGUAGE


Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the subset of patients with lung cancer which would derive the most benefit from immunotherapy.

Patients with lung cancer who have a high expression of PD-L1—in more than 50% of cells—are found to benefit from PD-L1 monotherapy. It is not certain whether this is the best way to indicate eligibility for immunotherapy.

Although, with the recent approval of pembrolizumab (Keytruda), this subset of patients should also be considered for upfront immunotherapy, says Papadimitrakopoulou.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x